
Mechanism Based Stratification of Patient-Level Data

Holger Fröhlich 30.11.2018



A Hypothetical Molecular Mechanism Based Disease **Taxonomy**









Realizing a Mechanism Based Disease Taxonomy

1.) Mechanism based stratification within separate diseases



2.) Joint AD/PD stratification by shared mechanisms






NeuroMMSig Mechanisms can be Linked to Alzheimer's Disease Risk


Machine learning based prediction of time to AD diagnosis

time

Multi-scale data (ADNI, ~900 normal / MCI patients):

- Clinical features, incl. neuropsychological assessment scores
- SNPs
- Genetic (pathway) features
- Neuro-imaging features






External validation with AddNeuroMed ongoing




Realizing a Mechanism Based Disease Taxonomy

1.) Mechanism based stratification within separate diseases



2.) Joint AD/PD stratification by shared mechanisms





Which omics data to use?

| | | | AD | | | | | | | PD | | |
|----------------------|-------|--------|---------|---------|-----|------|-----|-------|---------|--------------|-----|----------|
| | ADNI | ROSMAP | IDIBAPS | INSIGHT | UKB | PPMI | | DIGPD | ICEBERG | AETIONOMY PD | KCL | Tübingen |
| N (disease cases) | 486 | | 537 | | 22 | 0 | 362 | | | 733 | | 232 |
| SNPs | | | | | | | | | | | | |
| genome-wide DNA m | ethyl | | | | | | | | | | | |
| proteomics | | | | | | | | | | | | |
| CHIPseq | | | | | | | | | | | | |
| RNAseq | | | | | | | | | | | | |
| inflammation markers | 5 | | | | | | | | | | | |

Initially only ADNI + PPMI available

• Choose ADNI + PPMI as discovery cohorts for joint AD/PD stratification. Others for validation purposes.

Largely rely on genotype based stratification


- Data availability
- Significant genetic disease component (Arenson et al., Journal of Genetics, 2018)

Other data used for biological contextualization



An Approach for Mechanisms Based Patient Stratification

Unsupervised joint clustering of Alzheimer's + Parkinson's patients





Most Discriminating Mechanisms in Detail

| Subgraph Number | Genes in subgraph | Subgraph | Neighbourhood of the subgraph |
|-----------------|-------------------|--|--|
| Subgraph 5 | MTHFR | Outriess Outriess Outriess Outriess Outriess Outriess | |
| Subgraph 10 | IL18, NLRP3 | 9 1.18 | |
| Subgraph 12 | AKT1 | ⊕ Act1 | Service of the servic |
| Subgraph 13 | МАРК9 | о мата | 0.000 |

NeuroMMSig mechanisms

Cluster 3

Cluster 2

Cluster 1

Cluster 4


- Follate metabolism (AD)
- Vitamin metabolism (AD)
- Epigenetic modification (PD)
- IL signaling (AD, PD)
- Caspase signaling (AD, PD)
- AKT/mTOR signaling (AD, PD)
- GBR10 signaling (PD)
- Nerve growth factor (AD)
- Matrix metalloproteinase (AD)


MAPK signaling (AD, PD)


Joint sparse NMF based (bi-)clustering of ADNI + PPMI genotypes




Clusters are confirmed in Validation Data








IGP = proportion of samples in a cluster, whose nearest neighbors are also in the same cluster. (Kapp & Tibshirani, 2007)








- MIF (PD)
- TYRO3 (PD)




Clusters express differences in neuroinflammation and motor symptoms in PD

Association to Clinical Variables in PPMI and ADNI



P < 0.01 at all time points



Association of brain volume shrinkage and neuroinflammation: Datta et al., Brain 2017

Association of clusters to tremor severity in PD and inter-cranial brain volumes in AD.



Summary of Key Achievements

Novel Data Science methods confirm relevance of knowledge derived disease mechanisms


- predicting disease onset: AD risk model (Khanna et al., Sci Rep, 2018)
- mechanism based patient stratification

Stratification has been validated in integrated AD and PD cohorts

Downstream analysis ongoing

Identified patient sub-groups differ in

- neuroinflammation
- motor symptoms (PD)
- inter-cranial brain volumes (AD)





Acknowledgements

Fraunhofer SCAL

- Asif Emon
- Daniel Dominguez-Fernandez
- Shashank Khanna
- Anandhi Iyappan
- Colin Birkenbihl
- Reagon Kharki
- Martin Hofmann-Apitius

UCB

- Ashley Heinson
- Ping Wu
- Johann de Jong
- Ashar Ahmad
- Phil Scordis



Backup



Linking to Biological Mechanisms – Two Examples

Suggested in Nighot et al., 2016 A)



OpenBEL (Kodamulliletal., 2015) Pathway mapping for OpenBEL:
NeuroMMSig (Domingo-Fernandez et al.,
Bioinformatics, 2017)

BECN

BECN

BECN


BAPBA2

BAGS

Insulin signaling – NK cell mediated cytotoxicity


Suggested in Lorini et al., 1994









Options for Identifying a Mechanism Based Disease Subtypes





Joint AD/PD Clustering Approach for Genotype Data (Discovery)







Validation with external data (example: ROSMAP)

Logistic regression classifier (discovery cohort)

 Cross-validated AUC (overoptimistic)

Assign ROSMAP patients to clusters


- Encode patients using 148 SNPs
- •ssGSFA
- Autoencoder (trained with ADNI + PPMI)

Evaluation

• IGP measure (Kapp & Tibshirani, 2007)

Contextualization

- Differential protein expression
- Differential gene expression
- Correlation with CpGs
- Correlation with histone marks (CHIPseq)






Mechanism Impact Score

SNP → gene mapping:

- proximity (Ensembl): +/- 50Kbp
- eQTLs (GTex database)

No. of rsID for each Subgraph



| | SNP1 | SNP2 | SNP3 | |
|-----------|------|------|------|--|
| Patient 1 | 0 | 0 | 2 | |
| Patient 2 | 2 | 1 | 0 | |
| Patient 3 | 1 | 2 | 0 | |
| | | | | |

| | SNP1 | SNP2 | SNP3 | |
|-----------|------|------|------|--|
| Patient 1 | 0 | 0 | 2 | |
| Patient 2 | 2 | 1 | 0 | |
| Patient 3 | 1 | 2 | 0 | |
| | | | | |

Mechanism 1

Mechanism N

Aggregate scores of member SNPs:

- PCA
- Autoencoder networks
- ssGSEA



Patient specific mechanism impact profile by

| | Mechanism 1 | Mechanism 2 | Mechanism 3 | |
|-----------|-------------|-------------|-------------|--|
| Patient 1 | | | | |
| Patient 2 | | | | |
| Patient 3 | | | | |
| | | | | |




No robust clustering with raw genotype and PCA based aggregation

Raw genotype + sparse NMF

| Clusters | AD | PD | Total | SI |
|-----------|-----|-----|-------|----|
| Cluster 1 | 190 | 134 | 324 | 1 |
| Cluster 2 | 296 | 224 | 520 | 1 |


PCA + sparse NMF

| Clusters | AD | PD | Total | SI |
|-----------|-----|-----|-------|-------|
| Cluster 1 | 102 | | 102 | 1 |
| Cluster 2 | 384 | 358 | 742 | 0,95 |
| | | | | 0,975 |




Dashed = $10 \times r$ randomly shuffled data





BoxPlots of orginial and random PCA AD-PD clusters SI




Clusters are probably random artifacts.





Robust clustering with ssGSEA and autoencoder based SNP aggregation


ssGSEA + sparse NMF


| see | d_ica_r | ank_2:1 | 0_nrun_5 | 0 |
|-----------|---------|---------|----------|----|
| Clusters | AD | PD | Total | SI |
| Cluster 1 | 65 | 27 | 92 | 1 |
| Cluster 2 | 80 | 65 | 145 | 1 |
| Clusrer 3 | 81 | 53 | 134 | 1 |
| Cluster 4 | 88 | 83 | 171 | 1 |
| Cluster 5 | 172 | 130 | 302 | 1 |
| | | | | |












onsensus map of Clustering between AD and PD




No. of cluster confirmed with PAC index analysis (Senbabaoglu et al., Sci Rep 2014).

Clusters are highly stable and clearly better discriminated than random data




Association of Mechanisms to different Clusters

ssGSEA + sparse NMF




Autoencoder + sparse NMF





WholeBrain.m24: p = 0.059






AETIONOMY: Vision & Key Challenges

Developing a "mechanism-based" taxonomy of Alzheimer's and Parkinson's Disease

- Current classification of neuro-degenerative diseases is purely phenotype based
- Vision: a molecular mechanism based classification
 - Potentially new ways of treating patients
- Project goal: first proof of principle



Scientific Approach in AETIONOMY

